A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study will help determine whether 2 doses of the combination (ipilimumab + nivolumab) is
sufficient for patients with early benefit compared to the usual way of trying to give 4
doses. If patients do not show early benefit after 2 doses, patients will be able to continue
with additional ipilimumab + nivolumab, even beyond the standard 4 doses if felt in the best
interest of the patient.